Fact-checked by Grok 2 weeks ago

Tren

Trenbolone, commonly known as Tren, is a synthetic anabolic-androgenic (AAS) belonging to the nandrolone group, characterized by its high potency in promoting muscle growth and protein synthesis with strong anabolic and androgenic effects. Developed in 1963 by a team of chemists led by Louis Velluz at Roussel-Uclaf, it was initially created as a veterinary pharmaceutical to enhance and in , particularly . Trenbolone is administered in ester forms, such as and , which are implanted in to improve feed efficiency and increase average daily gain by 10-30%, resulting in greater carcass weights (typically 5-10% higher) through accelerated muscle accretion and reduced fat deposition. These applications have made it a staple in the animal industry since the 1970s, though residues in have raised environmental and concerns due to its persistence as an in ecosystems. Despite lacking approval for human medical use by regulatory bodies like the FDA, Trenbolone is widely abused illicitly by bodybuilders, athletes, and fitness enthusiasts for its high anabolic and androgenic potency, up to five times that of testosterone, enabling rapid gains in strength, muscle density, and vascularity during both bulking and cutting phases. Its non-aromatizing nature minimizes water retention and gynecomastia risks compared to other AAS, but this comes at the cost of profound side effects, including aggression ("Tren rage"), insomnia, night sweats, cardiovascular strain, liver and kidney damage, and suppression of natural testosterone production. The steroid's black-market prevalence has surged in recent years, fueled by trends among younger demographics seeking extreme physiques, yet its Schedule III controlled substance status in the United States and similar bans worldwide highlight the severe legal and health repercussions of non-veterinary use.

Overview

Definition and Classification

, commonly abbreviated as "Tren" in and athletic communities, is a synthetic anabolic-androgenic (AAS) characterized by its potent anabolic effects and derivation from . It belongs to the class of 19-nortestosterone derivatives, featuring structural modifications including additional double bonds in the that enhance its anabolic potency relative to its androgenic activity. As a member of the family, has never been approved or marketed for human medical use, though it is employed in veterinary applications to promote growth in . The compound is identified by its International Union of Pure and Applied Chemistry (IUPAC) name, 17β-Hydroxyestra-4,9,11-trien-3-one, with a molecular formula of C₁₈H₂₂O₂ and (CAS) registry number 10161-33-8.

Chemical Structure and Properties

Trenbolone, systematically named (17β)-17-hydroxyestra-4,9,11-trien-3-one, is a synthetic and a derivative of . Its molecular formula is C₁₈H₂₂O₂, corresponding to a molecular weight of 270.37 g/mol. The core structure consists of the four-ring backbone typical of androgens, lacking the 19-methyl group found in testosterone, with a Δ⁴ between carbons 4 and 5, conjugated s at Δ⁹ (between carbons 9 and 10) and Δ¹¹ (between carbons 11 and 12) that form a distinctive triene system, a group (=O) at carbon 3, and a β-hydroxyl group (-OH) at carbon 17. These modifications to the nandrolone scaffold, particularly the introduction of the Δ⁹,¹¹-diene, enhance its and compared to the parent compound. In its pure form, presents as a crystalline . It exhibits a of 183–186 °C and is characterized by low water (practically insoluble, <0.1 mg/mL), reflecting its highly lipophilic nature, while showing moderate in organic solvents such as (approximately 2 mg/mL) and higher in DMSO (20 mg/mL).

Medical and Veterinary Uses

Veterinary Applications

Trenbolone acetate is primarily used in for growth promotion in , particularly , where it enhances muscle mass, improves feed efficiency, and stimulates appetite to accelerate during the finishing phase. This anabolic agent works by promoting protein synthesis and nitrogen retention, leading to leaner carcasses with reduced fat deposition. In practice, it is administered to feedlot steers and heifers to optimize production efficiency in animal . The most common form is trenbolone acetate, marketed as subcutaneous implants such as Finaplix-H (for heifers: 200 mg via 10 pellets, administered in the last 63 days prior to slaughter) and Finaplix-S (for steers: 140 mg via 7 pellets, with sustained effects typically up to 100 days). These implants are placed in the , releasing the drug slowly over time. Studies have shown this administration results in 15-20% greater overall compared to non-implanted , with average daily gains increasing by 17-26% across breeds. In agricultural applications, trenbolone acetate offers significant benefits by improving nitrogen retention, which enhances protein utilization and reduces nitrogen excretion by up to 8%, thereby lowering the environmental footprint of production. For instance, its use in has been associated with an 11% improvement in feed efficiency, a 7% increase in carcass weight, and a 5% larger ribeye area, contributing to more sustainable resource use per unit of produced, including reductions in carbon emissions by 8%, by 6%, and consumption by 4%. These outcomes are supported by research demonstrating decreased land requirements and in implanted herds.

Illicit Human Use

Trenbolone has been illicitly used by humans for performance enhancement since the early , initially gaining popularity among professional bodybuilders and athletes in Western societies for its potent anabolic effects. By the , usage had shifted predominantly to amateur athletes, comprising 70–80% of anabolic-androgenic steroid (AAS) users seeking aesthetic improvements or recreational performance gains, with global lifetime prevalence of AAS use estimated at 3.3% in 2014, disproportionately affecting men. In the , its adoption surged among younger demographics, particularly teens, fueled by platforms like , where trends such as the "30-day tren challenge" and influencers like the Tren Twins (with approximately 1.94 million subscribers as of November 2025) promoted its use for rapid physique transformation. Administration of for illicit human use typically involves of its forms, as the base compound is not suitable for direct use due to its short . The short-acting is commonly dosed at 50–100 every other day to maintain stable blood levels, while the longer-acting is administered at 200–400 per week, often in cycles lasting 6–12 weeks to maximize effects before a break. These regimens are frequently stacked with other AAS like testosterone to enhance outcomes, though users self-adjust based on online forums and anecdotal reports rather than medical guidance. Users perceive trenbolone as highly effective for achieving rapid lean muscle gains, with reports of up to 20 pounds of mass added in a single cycle, alongside significant fat loss and improved muscle density without the water retention associated with estrogen-converting steroids. This profile makes it particularly appealing in for contest preparation, where a hard, vascular appearance is prioritized. Illicit trenbolone is primarily sourced from the , often diverted from veterinary supplies intended for implants or produced in underground laboratories, leading to frequent issues with product purity and . In recent years, has facilitated easier access, with purchases arranged via platforms like , Telegram, or even payment apps such as , bypassing traditional suppliers. Systematic analyses of black-market AAS reveal that a substantial proportion are or substandard, heightening risks from unknown compositions.

Pharmacology

Pharmacodynamics

Trenbolone binds to the (AR) with high affinity, approximately three times greater than that of testosterone, enabling potent activation of AR-mediated signaling pathways. This binding affinity underpins its strong anabolic effects, characterized by approximately 8–10 times the anabolic potency and 3–5 times the androgenic potency of testosterone, resulting in a higher anabolic-to-androgenic ratio. These estimates are based on animal models, such as the Hershberger assay, with limited direct human data available. Upon AR activation, promotes protein synthesis and nitrogen retention in muscle tissues, facilitating increased accumulation. It also stimulates production through enhanced , improving oxygen transport and endurance. Additionally, binds to receptors, antagonizing their catabolic effects and further supporting an anabolic state by reducing protein breakdown. Beyond AR-mediated actions, exhibits progestogenic activity by binding to the with affinity slightly higher than that of progesterone itself, which can lead to unique side effects such as or in some users due to elevated levels.
SteroidAnabolic RatingAndrogenic RatingNotes on Relative Potency
Testosterone100100Reference standard.
12537Lower androgenic activity than .
800–1000300–500Approximately 6–8x more anabolic and 8–14x more androgenic than ; 8–10x anabolic and 3–5x androgenic vs. testosterone.

Pharmacokinetics

Trenbolone exhibits poor oral due to extensive first-pass in the liver, necessitating administration as prodrugs via to achieve effective systemic exposure. The of trenbolone, commonly used in veterinary applications, provides rapid onset with an elimination of approximately 1–2 days, while the enanthate extends this to 8–10 days, allowing for less frequent dosing. Intramuscular administration of these esters results in nearly complete , as the is cleaved by esterases to release the active parent compound. The of esters follow elimination , where the (t_{1/2}) is calculated as t_{1/2} = \frac{0.693}{k_{\text{elim}}}, with k_{\text{elim}} representing the . For trenbolone acetate, typical k_{\text{elim}} values yield a t_{1/2} of 1–2 days, derived from observed clearance rates in models extrapolated to use. Similarly, the longer enanthate ester's t_{1/2} of 8–10 days reflects slower release and elimination, influencing dosing intervals in illicit applications. Trenbolone undergoes hepatic metabolism primarily mediated by 3A4 (), producing key metabolites such as 17α-trenbolone (also known as 17α-epi-trenbolone) and trendione. This epimerization at the 17-position is a major pathway, with 17α-trenbolone predominating in excreta. Unlike aromatizable androgens like testosterone, trenbolone lacks the structural prerequisites for conversion to estrogens, resulting in no significant . Excretion of and its metabolites occurs mainly via (approximately 60–70%) and (20–30%), with the remainder through biliary routes. In doping control scenarios, urinary detection of trenbolone metabolites, such as 17α- and 17β-trenbolone, is possible for up to 30 days following administration, depending on dose, ester type, and analytical .

Adverse Effects

Common Side Effects

One of the most distinctive short-term adverse reactions to trenbolone acetate injection is "Tren cough," an acute episode of intense coughing that occurs immediately after administration and typically lasts 5-10 minutes. This reaction results from pulmonary oil microembolism (), where small amounts of the oil-based carrier from the injection enter the bloodstream and irritate the lungs, causing temporary respiratory distress. Although generally self-limiting and not life-threatening, Tren cough can be alarming and is reported frequently among users due to the compound's intramuscular delivery method. Trenbolone's potent androgenic properties contribute to several common dermatological and behavioral side effects. Users often experience severe , particularly on the back and shoulders, driven by increased sebum production and follicular . or accelerated male-pattern baldness is another frequent issue, especially in those genetically predisposed, as the binds strongly to receptors in follicles. , colloquially known as "Tren rage," manifests as heightened , verbal outbursts, and , with studies showing a significant association between higher doses and increased among anabolic-androgenic (AAS) users. and are also prevalent, often linked to the compound's elevation of body temperature and disruption of cycles, with qualitative reports from users describing severe "trensomnia" and profuse sweating that impairs rest. Cardiovascular effects are commonly observed shortly after initiating trenbolone use, including elevated and increased . These arise from the steroid's androgenic effects, including potential increases in production and vascular strain. User surveys and case studies from the indicate that up to 90% of trenbolone users encounter some injurious side effects, with affecting a substantial majority and reported in approximately half of cases. Due to its status, much of the data on adverse effects comes from , case reports, and user surveys, which may be subject to reporting bias.

Long-Term Health Risks

Prolonged exposure to , a potent synthetic anabolic-androgenic (AAS), significantly disrupts the endocrine system through inhibition of the hypothalamic-pituitary-gonadal axis, leading to profound suppression of natural testosterone production. In , trenbolone administration has been shown to reduce testosterone levels by 80% in intact males within 10 days, exacerbating and requiring extended post-cycle therapy for partial recovery. This suppression often persists long-term in former users, similar to findings in former AAS users where 27% exhibit testosterone levels below clinical reference limits even after cessation. Additionally, trenbolone's progestogenic properties can elevate levels and contribute to , which affects approximately 33% of users. Chronic endocrine disruption also impairs , resulting in that may last months to years, as exogenous androgens like trenbolone inhibit and secretion. Trenbolone use is associated with substantial organ damage over time, particularly affecting the liver, heart, and . Although injectable forms like trenbolone acetate are less hepatotoxic than oral AAS, prolonged use can still elevate liver enzymes and induce , potentially leading to or as seen in broader AAS cohorts. Cardiovascular risks are more pronounced, with long-term exposure promoting , , and through activation of the renin-angiotensin-aldosterone system and increased oxidative damage; case reports link trenbolone specifically to in young users. Renal strain manifests as glomerular injury and , with animal models demonstrating dose-dependent kidney damage and from AAS like , a , highlighting similar mechanisms for trenbolone. Mental health consequences of extended trenbolone use include a high potential for , driven by withdrawal-induced that mimics severe mood disturbances. Former AAS users, including those exposed to potent compounds like , report elevated rates of anxiety and post-cycle, with studies indicating 13.3% seeking treatment for compared to 5% in non-users, often linked to dysmorphia and neurochemical imbalances. These effects can persist, contributing to prolonged psychiatric syndromes such as or major depressive episodes, exacerbated by the steroid's impact on brain reward pathways. Regarding cancer risks, trenbolone's strong androgenic potency may promote tumor growth in hormone-sensitive tissues, as evidenced by studies showing enhanced proliferation of human cells via the Akt/ signaling pathway. Animal models further indicate that supraphysiological doses can induce enlargement and act as tumor promoters, mirroring broader AAS effects on androgen receptor-driven . In males, elevated from progestogenic activity raises theoretical concerns for progression, though direct evidence remains limited to general AAS associations with tumors.

History and Development

Synthesis and Early Research

Trenbolone, chemically known as 17β-hydroxyestra-4,9,11-trien-3-one, was first synthesized in 1963 by a team of chemists led by Louis Velluz at the pharmaceutical company Roussel-Uclaf. The synthesis employed a partial synthetic approach starting from , involving key modifications to the nucleus, such as the introduction of a triene system in rings A and B to enhance anabolic potency while minimizing androgenic side effects. This work built on earlier advances in chemistry at Roussel-Uclaf, resulting in a compound patented that same year under patent M1958 for its base form and ester. Early research in the mid- focused on evaluating 's anabolic properties through animal trials, primarily in and rats, where it demonstrated superior retention and protein compared to testosterone, leading to enhanced muscle and improved feed efficiency. These studies highlighted trenbolone's high anabolic-to-androgenic , estimated at 500:500 relative to testosterone's 100:100, positioning it as a promising for veterinary applications. By the late , patents for its esters, such as M5979 () for the 17-cyclohexylmethylcarbonate form, supported its development for use as a growth promoter in . In the 1970s, research confirmed trenbolone's non-aromatizing nature and its ability to bind progesterone receptors, reducing certain estrogen-related effects in animal models. Unlike other anabolic-androgenic steroids, trenbolone was not pursued for human medical applications due to preclinical evidence of toxicity, including and cardiovascular strain, restricting it to veterinary contexts. Early publications from this era documented these findings, emphasizing trenbolone's tissue-selective anabolic effects in preclinical models.

Commercial Introduction and Regulation

Trenbolone acetate was commercially introduced in the United States in 1987 by Hoechst-Roussel Agri-Vet Company under the brand name Finaplix, formulated as subcutaneous ear implants to promote growth in . The product line included Finaplix-H for heifers and steers, delivering 200 mg of trenbolone acetate per implant to enhance feed efficiency and prior to slaughter. FDA approval for these veterinary implants was granted on July 2, 1987, under NADA 138-612, establishing trenbolone acetate as a key tool in U.S. production. By the , Finaplix implants achieved widespread adoption in the U.S. , with steady increases in usage reflecting their efficacy in improving average daily gains by up to 20% in . Subsequent company mergers in the and shifted production to new sponsors, such as Intervet Inc., with continued FDA supplements and generic alternatives. Regulatory frameworks for trenbolone acetate emphasize its veterinary exclusivity while prohibiting human applications. In the United States, it remains approved solely for animal use by the FDA, but the Anabolic Steroid Control Act of 1990 designated it a Schedule III under the , criminalizing non-veterinary possession, distribution, or manufacture. The European Union imposed a comprehensive ban on hormone-treated meat imports in 1989, encompassing trenbolone residues and prohibiting trade in beef from implanted animals to address consumer health concerns. Internationally, variations persist: veterinary use is permitted in under strict APVMA oversight for growth promotion in , but human possession or supply without authorization is illegal as a . Globally, is banned for human use under frameworks like the World Anti-Doping Agency's prohibited list. In 2025, an INTERPOL-coordinated across 90 countries seized over 50 million doses of illicit pharmaceuticals valued at USD 65 million, reflecting ongoing efforts against online trade in s.

Society and Culture

Use in Bodybuilding and Athletics

, a potent anabolic-androgenic originally developed for veterinary use, has been widely adopted in subcultures for its ability to promote significant muscle growth and fat loss. Bodybuilders typically incorporate it into cycles lasting 6 to 18 weeks, often pairing it with testosterone as a base to support hormonal balance and enhance overall anabolic effects. This practice aims to maximize lean mass gains while minimizing estrogenic side effects associated with solo use. Within , is particularly favored as a cutting agent during contest preparation phases, where athletes seek to reduce body fat while preserving muscle definition for competitions. Its popularity in this context emerged prominently in the , as users reported superior results in achieving a "hard" and vascular compared to other steroids. In , is classified as a non-specified anabolic agent under S1.1 of the (WADA) Prohibited List and has been banned at all times since WADA's establishment in 1999. It has been implicated in doping violations across , including a notable doping case involving U.S. sprinter Erriyon Knighton, who tested positive for trenbolone metabolites in March 2024 and was handed a 4-year ban by the Court of Arbitration for Sport in September 2025. Such detections highlight its illicit use for performance enhancement in elite competitions, despite rigorous testing protocols. Recent trends indicate a surge in trenbolone's popularity among young males aged 18-25, driven by viral content on platforms like and promoting it for attaining a "shredded" with minimal water retention. As of January 2025, experts noted a rise in use among men due to pressures from body dysmorphia, with amplifying idealized body standards. This shift reflects broader pressures in , where influencers showcase rapid transformations, often targeting novice users seeking aesthetic gains. Stacking practices are common in to amplify effects, with frequently combined with oral steroids like Dianabol for bulking phases or Winstrol for enhanced cutting and strength. Qualitative reports from users emphasize 's role in these combinations for notable improvements in size and power output, often described as superior to standalone use. , classified as a Schedule III controlled substance under the U.S. , is approved for veterinary use in growth promotion with a valid prescription but is illegal for consumption or without medical authorization. or use constitutes a offense, with simple punishable by up to one year in prison and a fine for first-time offenders, escalating to charges for or intent to distribute, which can result in up to five years imprisonment and fines up to $250,000. Enforcement by the (DEA) has intensified, with anabolic-androgenic steroid (AAS) laboratory seizures showing notable increases amid online proliferation. Internationally, trenbolone is prohibited by the (WADA) and the (IOC) as an anabolic agent, banning its use in competitive sports year-round. In the , the import and sale of meat from animals treated with trenbolone are strictly prohibited under hormone residue regulations to protect public health. Canada designates trenbolone as a Schedule IV substance under the , making unauthorized possession, trafficking, or production punishable by up to three years imprisonment for indictable offenses. Challenges in enforcement stem from the rise of online sales, particularly on the , where anonymous platforms facilitate global distribution of trenbolone and other AAS, complicating jurisdictional efforts by law enforcement agencies like the and . In the , trenbolone falls under Class C drugs, with trafficking penalties reaching up to 14 years in and unlimited fines, reflecting stringent controls on importation and supply. For example, New York's 2025 legislation (S5413) provides for random testing in public and private school athletes, allocating $1,000,000 to enhance detection and education programs.

Environmental Impact

Persistence in the Environment

Trenbolone acetate and its primary metabolites, such as 17α- and 17β-trenbolone, exhibit high lipophilicity, with octanol-water partition coefficients (log Kow) ranging from 2.7 to 3.1, which enhances their resistance to microbial and photolytic degradation in environmental matrices. In agricultural soils under aerobic conditions, half-lives are relatively short, typically on the order of hours to days; however, persistence increases substantially in anaerobic environments like stored manure, where the 17α-trenbolone isomer has a reported half-life exceeding 200 days. In aqueous systems, initial degradation half-lives are brief (often less than 1 day under light exposure), but reversion processes—where photodegradation products reform bioactive parent compounds—extend effective environmental persistence, particularly in hyporheic zones of streams. The primary entry pathway for into the environment stems from runoff associated with veterinary implants used in production, particularly from operations where and are common sources. Monitoring by the U.S. Geological Survey (USGS) in the early 2000s has detected trenbolone metabolites in U.S. rivers at concentrations of 1-10 ng/L, often downstream of agricultural areas, highlighting ongoing contamination from these nonpoint sources, with subsequent reviews confirming similar low-level detections. These low-level detections underscore the compound's mobility via transport despite its lipophilic nature. Due to its favorable log Kow, tends to into s rather than remain dissolved, facilitating accumulation in benthic environments near agricultural discharge sites. Recent studies from 2020-2025 indicate that persists through conventional processes, with incomplete removal in systems leading to concentrations that contribute to downstream deposition. Environmental monitoring of anabolic-androgenic steroids (AAS) like in agricultural settings is guided by U.S. Environmental Protection Agency (EPA) frameworks for concentrated animal feeding operations (CAFOs), which emphasize runoff control and periodic assessments to track residues. These guidelines, informed by post-2020 , reveal gaps in assumptions and advocate for enhanced surveillance to address persistence in manure-amended soils and adjacent waterways.

Effects on Aquatic Life

Trenbolone, primarily in its 17β form, acts as a potent agonist in , leading to significant endocrine disruption at environmentally relevant concentrations. Exposure to levels as low as 4–87 ng/L has been shown to masculinize female , inducing male secondary sexual characteristics such as nuptial tubercles in species like fathead minnows (Pimephales promelas) and Japanese medaka (Oryzias latipes). In s, higher concentrations can paradoxically induce vitellogenin production, an estrogen-responsive protein typically associated with , though the dominant effects are androgenic. These disruptions alter sex steroid synthesis, reducing plasma testosterone and 17β-estradiol levels, and can skew sex ratios toward s, with studies reporting up to 100% male offspring in (Danio rerio) at concentrations around 20 ng/L during early development. Reproductive impacts are pronounced, with short-term exposures reducing across multiple ; for instance, production in fathead minnows declined by up to 70% at 27–87 ng/L. In (Oncorhynchus mykiss), parental exposure to 35 ng/L for 60–77 days did not significantly affect embryonic survival rates (remaining above 80%), but caused developmental delays, such as underdeveloped eyes in embryos at 19 days post-fertilization. These effects stem from runoff-contaminated waters near agricultural sites, where persists and bioaccumulates in aquatic organisms. Recent wildlife studies highlight broader implications for amphibians, with a 2023 investigation exposing (Litoria ewingii) tadpoles to 4.6–11.2 ng/L for 14–21 days revealing increased somatic growth (longer and heavier individuals) and altered behaviors, including heightened baseline activity but reduced response to simulated predators, potentially increasing predation risk. While direct in birds via the remains understudied, trenbolone's lipophilic nature suggests trophic transfer potential, as evidenced by immunotoxic effects in (Coturnix japonica) from controlled exposures, including disrupted bursa development and altered leukocyte profiles. Ecosystem-level changes include inhibition of microbial communities in river sediments, where trenbolone reduces N-acetyl-glucosaminidase enzyme activity by approximately 50%, impairing nutrient cycling processes like degradation without altering overall bacterial diversity. Trace levels of (up to 120 ng/L in discharges, <10 ng/L downstream) have been detected in river waters, posing risks to and indirect exposure through sourced from contaminated rivers, though concentrations typically fall below health advisory limits. Mitigation efforts are hampered by incomplete global regulatory coverage; while the has prohibited trenbolone implants in since 1988 due to environmental concerns, usage persists in regions like the , prompting ongoing calls for expanded bans in sensitive watersheds to protect ecosystems. As of 2025, the persists in disputes, with calls for expanded monitoring in sensitive watersheds, though no new U.S. federal bans on trenbolone implants have been implemented.

References

  1. [1]
    Trenbolone: Uses, Interactions, Mechanism of Action - DrugBank
    Feb 26, 2016 · Trenbolone, also known as trienolone or trienbolone, is a steroid used on livestock to increase muscle growth and appetite.
  2. [2]
    Impact of trenbolone on selected organs - PubMed
    Trenbolone is a synthetic analogue of testosterone, belonging to the nandrolone group. It has both a strong anabolic effect and a limited androgenic effect ...
  3. [3]
    17β-Trenbolone - American Chemical Society
    Dec 31, 2013 · 17β-Trenbolone is an anabolic steroid synthesized in 1963 by L. Velluz and co-workers. Veterinarians use it, most commonly as an ester, to increase muscle ...<|control11|><|separator|>
  4. [4]
    Trenbolone Acetate - an overview | ScienceDirect Topics
    Trenbolone acetate is a synthetic anabolic-androgenic steroid, widely used as a growth promotor in beef feeder systems for improved production of muscle mass ...
  5. [5]
    What is Trenbolone and what are its side effects?
    Sep 11, 2024 · Trenbolone acetate is a synthetic anabolic steroid of the nandrolone group. It was designed to increase muscle growth and appetite in livestock.
  6. [6]
    Why You Should Think Twice Before Using Trenbolone
    Jan 1, 2025 · Trenbolone is an anabolic steroid meant for veterinary use, not human use. Learn the drawbacks of trenbolone and how it can affect your ...
  7. [7]
    Trenbolone - an overview | ScienceDirect Topics
    Trenbolone acetate is a synthetic anabolic-androgenic steroid, widely used as a growth promotor in beef feeder systems for improved production of muscle mass ...
  8. [8]
    Trenbolone | C18H22O2 | CID 25015 - PubChem - NIH
    Trenbolone | C18H22O2 | CID 25015 - structure, chemical names, physical and chemical ... Molecular Formula. C18H22O2. Synonyms. Trenbolone; 10161-33-8; 17beta ...
  9. [9]
    Nandrolone Derivative - an overview | ScienceDirect Topics
    Nandrolone derivatives are steroids that are synthesized from 19-nortestosterone, possessing similar anabolic properties to testosterone but with reduced ...
  10. [10]
    What to Know About Trenbolone: The Viral Steroid Targeting Teens
    Sep 5, 2024 · How trenbolone (aka tren), an obscure bovine steroid, became gym Gen Z's favorite social media muscle flex.
  11. [11]
    Trenbolone | 10161-33-8 - ChemicalBook
    Aug 6, 2025 · Trenbolone (CAS 10161-33-8) information, including chemical ... Molecular Formula: C18H22O2. Molecular Weight: 270.37. MDL Number ...Missing: IUPAC | Show results with:IUPAC
  12. [12]
    Identification of Trenbolone Metabolites Using Hydrogen Isotope ...
    Trenbolone (Tren) belongs to the class of synthetic anabolic-androgenic steroids (AAS) and is structurally characterized by a 4,9,11-triene-3-one structure ...Missing: triple | Show results with:triple
  13. [13]
    Trenbolone acetate (Ref: RU 1697) - AERU
    Trenbolone acetate exhibits stereoisomerism, specifically geometrical and optical isomerism, due to its multiple chiral centres and conjugated double bonds.
  14. [14]
    EP4001289A1 - Improved process for the preparation of trenbolone ...
    Tronbolone acetate has the following chemical formula (I-a):. Figure imgb0001. and chemical name is 17beta-acetoxy-estra-4,9,11-triene-3-one. [0007]. The ...
  15. [15]
    Anabolic Steroids in Fattening Food-Producing Animals—A Review
    Another study conducted on cattle shows that the use of anabolic implants reduces water consumption by 9.85%, the need for sown land by 9.58%, greenhouse gas ...
  16. [16]
    Steroid Hormone Implants Used for Growth in Food-Producing ... - FDA
    Oct 24, 2024 · FDA has approved a number of steroid hormone drugs for use in beef cattle and sheep. These drugs increase the animals' growth rate and the ...Missing: dosage benefits nitrogen retention
  17. [17]
    [PDF] History of the TBA Implant Database
    In 1987, the first trenbolone acetate (TBA) containing implants were approved by the FDA in the form of Finaplix-S® and Finaplix-H® (see: History of Growth ...Missing: veterinary | Show results with:veterinary
  18. [18]
    21 CFR 522.2476 -- Trenbolone acetate. - eCFR
    Do not use in animals intended for subsequent breeding or in dairy animals. Safety and effectiveness have not been established in veal calves. A withdrawal ...
  19. [19]
  20. [20]
    The Uses of Anabolic Androgenic Steroids Among Athletes - PMC
    Dec 29, 2023 · The heightened ability to build lean muscle mass and increase strength can contribute to enhanced athletic performance. AAS can accelerate ...
  21. [21]
    Fake anabolic androgenic steroids on the black market
    Jul 17, 2022 · With this systematic review and meta-analysis, we demonstrate that substantial mean proportions of black-market AAS are counterfeit and of substandard quality.Missing: veterinary | Show results with:veterinary
  22. [22]
    Trenbolone - an overview | ScienceDirect Topics
    TBA is a synthetic androgenic steroid. It has 8 to 10 times the anabolic potency of testosterone but is only 3 to 5 times as androgenic.
  23. [23]
    Characterisation of the affinity of different anabolics and synthetic ...
    Mar 27, 2007 · For comparison, different anabolics and synthetic hormones were also tested for their binding affinities. For 17β-trenbolone (17β-TbOH), the ...
  24. [24]
    'My mind pretty much went to mush': Trenbolone in P.I.E.D. community
    Mar 29, 2023 · Introduction There are a variety of harms associated with anabolic–androgenic steroids (AAS), with some AAS associated with an increased ...
  25. [25]
    Pharmacokinetics of anabolic steroids - PubMed
    Excretion of the compound and its metabolites takes place via the urine and faeces, usually taking several days to completely pass through the system.
  26. [26]
    Metabolism of anabolic steroids by recombinant human cytochrome ...
    Nov 26, 1999 · Metabolism of steroid hormones with anabolic properties was studied in vitro using human recombinant CYP3A4, CYP2C9 and 2B6 enzymes.
  27. [27]
    Identification of Metabolites of Trenbolone Acetate in Androgenic ...
    In the case of 17α-trenbolone, androgenic activity was increased to about 3-fold over media at test concentrations of 12–30 ng/L, but the concentration–response ...Missing: pharmacodynamics | Show results with:pharmacodynamics
  28. [28]
    Probing for new long-term metabolites of trenbolone by hydrogen ...
    The detection of trenbolone doping in routine sports drug testing programs is complex as methods utilizing gas chromatography/ mass spectrometry are complicated ...
  29. [29]
    Occurrence of Pulmonary Oil Microembolism After Testosterone ...
    This patient experienced a mild, nonproductive cough that resolved without intervention within 10 minutes. A 2016 meta-analysis supported that testosterone ...
  30. [30]
    Examining the association between trenbolone, psychological ...
    ... black market are often mislabelled or contain different compounds than ... bodybuilding communities and the negotiation of trenbolone risk. Doping in ...
  31. [31]
    17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue ...
    We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without ...
  32. [32]
    Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased ...
    Aug 17, 2016 · Former AAS abusers exhibited significantly lower plasma testosterone levels and higher frequencies of symptoms suggestive of hypogonadism than healthy control ...
  33. [33]
    Understanding and managing the suppression of spermatogenesis ...
    Jun 26, 2022 · The use of exogenous testosterone and anabolic steroids suppresses male fertility by augmenting this negative feedback inhibition centrally.<|separator|>
  34. [34]
    Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review
    Jan 19, 2021 · Anabolic-androgenic steroids (AASs) are a large group of molecules including endogenously produced androgens, such as testosterone, ...
  35. [35]
    Anabolic-androgenic steroids and cardiovascular risk - PMC
    The use/abuse of AAS is correlated with higher cardiovascular risks, and many AAS users/abusers had cardiovascular diseases.<|control11|><|separator|>
  36. [36]
    A Young Man with Myocardial Infarction due to Trenbolone Acetate
    Coronary Artery Disease (CAD) is a leading cause of death throughout the world (1). Over the four decades, a significant decrease has been observed in age- ...
  37. [37]
    Long-Term Psychiatric and Medical Consequences of Anabolic ...
    The problem of anabolic-androgenic steroid (AAS) abuse has recently generated widespread public and media attention. Most AAS abusers, however, ...
  38. [38]
    Veterinary drug, 17β-trenbolone promotes the proliferation of human ...
    Veterinary drug, 17β-trenbolone promotes the proliferation of human prostate cancer cell line through the Akt/AR signaling pathway.Missing: risk | Show results with:risk
  39. [39]
    Anabolic androgenic steroids and carcinogenicity focusing on ...
    Apr 10, 2018 · High doses of nandrolone (aromatizable) and stanozolol (non aromatizable), could potentially increase breast cancer risk because in cases of ...
  40. [40]
    The genotoxicity of trenbolone, a synthetic steroid - PubMed
    Trenbolone, a synthetic androgen is used as a growth promotant in animal ... trenbolone are devoid of genotoxic activity and are not initiators of cancer.Missing: risk | Show results with:risk
  41. [41]
    New approach to synthesis of trenbolone | Chemistry of Natural ...
    New approach to synthesis of trenbolone. Brief Communications; Published ... Velluz, G. Nomine, K. Bucourt, and J. Mathieu, C. R. Acad. Sci.,257, 569 (1963).Missing: method | Show results with:method
  42. [42]
    Radiolabelling of steroids: the synthesis of 17α-[4-(14) C]trenbolone
    The synthesis of 17α-[4-(14) C]trenbolone from 17α-[4-(14) C]estradiol was achieved in 8 steps and 3.1% overall yield to give material with a radiochemical ...
  43. [43]
    Trenbolone
    Title: Trenbolone · CAS Registry Number: 10161-33-8 · CAS Name: (17 · Additional Names: 4,9,11-estratrien-17 · Molecular Formula: · Molecular Weight: 270.37 · Percent ...
  44. [44]
    17β-trenbolone, an anabolic–androgenic steroid as well as an ...
    The ratio of 17β-trenbolone concentration in brain tissues to that in plasma of male rats reached the highest at 12 h. The ratio at 24 h was the highest for ...
  45. [45]
    Anabolic Steroid Toxicity - StatPearls - NCBI Bookshelf - NIH
    Androgenic-anabolic steroids (AAS) are widely missed worldwide as performance-enhancing agents. The use of AAS started in competitive sports and spread to ...
  46. [46]
    New approach to synthesis of trenbolone - Semantic Scholar
    In recent years, the anabolic steroid 17~-hydroxyestra-4,9,11-trien-3-one (trenbolone), obtained by the scheme for the total synthesis of steroids proposed ...Missing: nandrolone dehydrogenation primary source
  47. [47]
    [PDF] Beef Cattle Management Update - University Digital Conservancy
    FDA approved sale of these products on July 2, 1987. Since that time, feedlot use of Finaplix implants has increased steadily.
  48. [48]
    Federal Register, Volume 62 Issue 103 (Thursday, May 29, 1997)
    May 29, 1997 · ... approval of an abbreviated new animal drug application (ANADA) filed by Ivy Laboratories, Inc. The ANADA provides for the use of trenbolone ...
  49. [49]
    [PDF] Drug Fact Sheet: Steroids - DEA.gov
    What is their legal status in the United States? Anabolic steroids are Schedule III substances under the Controlled Substances Act. Only a small number of ...Missing: Australia 1990
  50. [50]
    Is Trenbolone Legal in Australia? - Lexology
    Mar 21, 2024 · Tren is a controlled substance and is illegal to possess or supply without a prescription or permit in Australia. Tren substances require a ...
  51. [51]
    Record 769 arrests, $65M illicit drugs seized globally
    Jun 25, 2025 · An INTERPOL-coordinated operation across 90 countries has resulted in the seizure of 50.4 million doses of illicit pharmaceuticals worth USD 65 million.
  52. [52]
    Anabolic androgenic steroid abuse in young males - PMC - NIH
    Anabolic steroids are mostly used in cycles with a duration between 6 and 18 weeks. The unproven rationale behind this strategy is to gain muscle mass and ...<|separator|>
  53. [53]
    Anabolic Steroids - StatPearls - NCBI Bookshelf - NIH
    Feb 6, 2025 · Anabolic steroids are synthetic derivatives of testosterone that have both medical applications and a high potential for misuse.
  54. [54]
    The Prohibited List | World Anti Doping Agency - WADA
    Jun 1, 2019 · The List of Prohibited Substances and Methods (List) indicates what substances and methods are prohibited in sport and when.Athletes & Support Personnel · Liste des interdictions · Footer
  55. [55]
    U.S. sprinter Erriyon Knighton gets 4-year ban for positive test ... - CBC
    Sep 12, 2025 · ... trenbolone residues at the level required to have caused the [positive test]," the court said. The ban that starts Friday is cut for the ...
  56. [56]
    Men face growing pressure to use steroids as studies show increase ...
    Jan 13, 2025 · Parents and experts are sounding the alarm about unregulated anabolic steroid use happening as a result of the pressure young men face to ...Missing: bodybuilding | Show results with:bodybuilding
  57. [57]
    Diversion Control Division | Controlled Substance Schedules
    Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high ...
  58. [58]
    [PDF] 2025 National Drug Threat Assessment - DEA.gov
    Illicit opioids, particularly illicitly manufactured fentanyl, remain the primary drivers behind the ongoing epidemic of drug overdose deaths in the United ...
  59. [59]
    [PDF] international standard - prohibited list - WADA
    Anabolic agents are prohibited. When administered exogenously, including but not limited to: S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS). S1 ANABOLIC AGENTS.
  60. [60]
    [PDF] Drugs and the darknet. Perspectives for enforcement, research and ...
    Illicit trade on darknet markets is one manifestation of the increasingly complex nature of transnational organised crime in the European Union (EU).
  61. [61]
    Drugs penalties - GOV.UK
    Up to 2 years in prison, an unlimited fine or both (except anabolic steroids - it's not an offence to possess them for personal use), Up to 14 years in ...
  62. [62]
    NY State Senate Bill 2025-S5413
    Feb 21, 2025 · Provides for random testing for anabolic steroids in athletes in public and private schools; appropriates $1000000 therefor.
  63. [63]
    Stereoselective Sorption by Agricultural Soils and Liquid−Liquid ...
    Aug 6, 2025 · Log Kow of TbO, 17␤Tb, and 17␣Tb is 2.63, 3.08, and 2.72, respectively [6]. Log Koc for TbO, 17␤Tb, and 17␣Tb is 3.38, 3.08, and 2.77, ...<|separator|>
  64. [64]
    The fate of trenbolone acetate and melengestrol acetate after ...
    The steroids trenbolone acetate (TbA) and melengestrol acetate (MGA) are licensed as growth promoters for farm animals in several meat-exporting countries.
  65. [65]
    Coupled reversion and stream-hyporheic exchange processes ...
    May 8, 2015 · We show increased exposure to the primary metabolite, 17α-trenbolone (17α-TBOH), and elevated concentrations of the still-bioactive primary ...
  66. [66]
    Water-Quality Data for Pharmaceuticals, Hormones, and Other ...
    Dec 2, 2022 · A network of 139 streams in 30 states were sampled and analyzed for 95 different OWCs using five new research methods developed by the US Geological Survey.
  67. [67]
    Bioavailability and fate of sediment-associated trenbolone and ...
    Oct 15, 2014 · The field bioaccumulation factors for the detected synthetic steroids ranged from 450 to 97,000 in bile, 450 to 65,000 in plasma, 2900 to ...Missing: Kow | Show results with:Kow
  68. [68]
    Steroid hormones in wastewater: Sources, treatments ...
    This review discusses the sources, the efficiency of available wastewater treatment techniques to remove these hormones from wastewater, their potential ...
  69. [69]
    Risk Assessment Evaluation for Concentrated Animal Feeding ...
    A Risk Management Evaluation (RME) to provide information to help plan research dealing with the environmental impact of concentrated animal feeding operations.
  70. [70]
    A critical review of the environmental occurrence and potential ...
    Apr 27, 2018 · The 17β-trenbolone isomer can affect androgen receptor signaling pathways in various vertebrate species at comparatively low concentrations/doses.
  71. [71]
    Effect of parental exposure to trenbolone and the brominated flame ...
    Eggs collected from trenbolone exposed trout were immediately used in fertilization trials at a similar sperm:egg ratio using sperm collected from unexposed ...
  72. [72]
  73. [73]
    Immunotoxicity of trenbolone acetate in Japanese quail - USGS.gov
    Jan 1, 2007 · This study shows that trenbolone acetate is teratogenic and immunotoxic in Japanese quail, and provides evidence that the quail immune system ...
  74. [74]
  75. [75]
    Identification of Metabolites of Trenbolone Acetate in Androgenic ...
    Trenbolone acetate is a synthetic anabolic steroid that is widely used in the United States to promote growth of beef cattle. Metabolites of trenbolone acetate ...Missing: patent Uclaf 1969
  76. [76]
    Beef hormone controversy - Wikipedia
    The beef hormone controversy or beef hormone dispute is a disagreement over the use of growth hormones in beef production.Missing: 1990s | Show results with:1990s